title: Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.
abstract: The time necessary for a treatment to become effective is crucial for patients and physicians but has been largely neglected in the reporting and comparison of clinical trials in dermatology. The aim of this systematic review is to determine the time until the onset of action (TOA) of systemic agents approved for moderate-to-severe psoriasis. Primary outcome is the TOA defined as the weighted mean time until 25% of the patients achieved a psoriasis area and severity index (PASI) 75 response. Among the biologics, infliximab has the shortest TOA (3.5 weeks), followed by ustekinumab (high dose 4.6/low dose 5.1 weeks/not weight adapted), adalimumab (4.6 weeks), etanercept (high dose 6.6/low dose 9.5 weeks), and alefacept (high dose 15.4 weeks/low dose: no data). Among the conventional treatments, good data are available for cyclosporine A (CsA; TOA: 6.0 weeks) and limited data are found for methotrexate (MTX; TOA: high dose 3.2/low dose 9.9 weeks). No data are available for fumaric acid esters and retinoids. This systematic review provides clinically relevant information on the onset of action of antipsoriatic agents, although the data currently available allow only a limited assessment. Psoriasis trials should consider including TOA as an additional outcome measure.
authors: Division of Evidence Based Medicine (dEBM), Department of Dermatology, Charité-Universitätsmedizin Berlin, Berlin, Germany. ander.nast@charite.de
authors: Alexander
authors: A
authors: Nast
authors: Birte
authors: B
authors: Sporbeck
authors: Stefanie
authors: S
authors: Rosumeck
authors: Delano
authors: D
authors: Pathirana
authors: Anja
authors: A
authors: Jacobs
authors: Ricardo Niklas
authors: RN
authors: Werner
authors: Jochen
authors: J
authors: Schmitt
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D003879:Dermatologic Agents